Read more about BIAL’s expansion.
BIAL enters the US and acquires “promising” Parkinson’s disease programmes
Author: Simge Eva DoganPublished: 8 October 2020
Prep: Cook: Serves:
Portugal-based pharmaceutical company BIAL has launched a new research centre, BIAL Biotech, in Massachusetts, US, which will focus on genetically defined Parkinson’s disease.
BIAL has also announced that it has acquired the Parkinson’s disease research programmes of Lysosomal Therapeutics Inc, as well as its research and development team and clinical programme for LTI-291 – a therapy designed to treat a genetic form of the condition.
António Portela, executive president of BIAL, said: “Our entry into the US with the creation of BIAL Biotech and the acquisition of the promising programmes from LTI, is a decisive step towards the fulfilment of our mission to contribute to improving the quality of life of people worldwide.
“The development of this new research centre in the US, is a landmark of enormous relevance for us. We are investing in science and research, through our direct presence in one of the most important research hubs in the world and in one of the most promising areas of medicine.”
Lead image: research and development department at BIAL
For more information on the latest Parkinson’s disease research please visit the EPDA website.
Share this story
Neurologists should ‘speak up’ about Covid vaccines for people with Parkinson’s, says study
Breaking barriers to vaccination in the Parkinson’s disease communityREAD MORE
Leading MEP declares Parkinson’s “a European priority issue”
Campaigners advocate for better EU policy towards Parkinson’sREAD MORE
Reimagining Parkinson’s healthcare: a patient-focused plan
A recent report suggests eight ways to improve Parkinson’s treatmentREAD MORE